<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227938</url>
  </required_header>
  <id_info>
    <org_study_id>AIS-A02</org_study_id>
    <nct_id>NCT04227938</nct_id>
  </id_info>
  <brief_title>Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD Versus Host Disease</brief_title>
  <acronym>Balance</acronym>
  <official_title>An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpine Immune Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpine Immune Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Balance study will assess the safety, tolerability, and efficacy of an investigational
      drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft
      versus host disease (aGVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIS-A02 is a Phase 1b open-label study of ALPN-101 administered to adult subjects with
      steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).

      It will be conducted at approximately 10 US sites. Up to 72 subjects will be enrolled in Part
      A (dose escalation) and up to 25 subjects will be enrolled in Part B (dose expansion).

      In each Part, safety and efficacy assessments will be performed throughout the dosing and
      follow-up periods, and multiple PK and PD samples will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single dose of ALPN-101 will be administered via intravenous (IV) infusion. Multiple, ascending dose levels will be evaluated in cohorts of 3-6 subjects in Part A. In Part B, a single dose level—as identified in Part A—is planned.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
    <description>The incidence, severity, and seriousness of AEs, including dose-limiting toxicities, assessed by CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until the date of best response, assessed up to 36 months</time_frame>
    <description>Assessed by MAGIC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the date of best response until disease progression, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until relapse, initiation of new systemic therapy, or non-relapse mortality; assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until disease (aGVHD)-related event or death due to any cause, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until progression or death due to any cause without prior progression, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy relapse/progression (MR)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until the date of relapse/progression of the primary malignancy, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until death due to any cause, assessed up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration (tmax) of ALPN-101</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of ALPN-101</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of ALPN-101</measure>
    <time_frame>From study Day 1 (dosing of ALPN-101) until Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Graft Vs Host Disease</condition>
  <arm_group>
    <arm_group_label>ALPN-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single dose of ALPN-101. In Part A, ascending dose levels of ALPN-101 will be evaluated. In Part B, a single dose level of ALPN-101—as identified in Part A—will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPN-101</intervention_name>
    <description>A single dose of ALPN-101 will be administered via intravenous infusion.</description>
    <arm_group_label>ALPN-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Status post first allogeneic stem cell transplantation (allo-SCT) from any donor
             source using any conditioning regimen.

          3. Grade Ⅱ-Ⅳ acute GVHD per Mount Sinai Acute GVHD international Consortium (MAGIC)
             criteria.

          4. Corticosteroid resistant or refractory as defined as any of the following:

               1. Progression of aGVHD within 5 days following initiation of treatment with ≥ 2
                  mg/kg/day of prednisone or equivalent;

               2. Failure to improve within 7 days following initiation of treatment with ≥ 2
                  mg/kg/day of prednisone or equivalent; or

               3. Incomplete response (failure to achieve Complete Response) after 28 days of
                  immunosuppressive treatment including steroids (treatment with ≥ 2 mg/kg/day of
                  prednisone or equivalent).

          5. Must agree to use appropriate contraception.

          6. Female subjects must not be pregnant or breastfeeding.

             In addition, the following criteria must be met prior to dosing with ALPN-101 on Day
             1:

          7. Karnofsky performance score ≥ 40.

          8. No evidence of an active, uncontrolled bacterial, viral, or fungal infection.

        Exclusion Criteria:

          1. Current veno-occlusive disease, or current treatment with dialysis or mechanical
             ventilation associated with GVHD.

          2. Prior donor lymphocyte infusion (DLI).

          3. Receipt of any live vaccine within 4 weeks of ALPN-101 dosing.

          4. Presence of any active malignant disease.

          5. Corticosteroid therapy at doses &gt; 1 mg/kg/day prednisone or equivalent for indications
             other than GVHD ≤ 7 days p ALPN-101 dosing.

          6. Treatment with any of the following ≤ 2 weeks prior to ALPN-101 dosing: targeted
             inhibitors of the CD28/CD80/86 pathway (e.g. abatacept, belatacept), targeted
             inhibitors of the ICOS/ICOSL pathway

          7. Initiation of treatment with salvage therapy &lt; 2 days prior to ALPN-101 dosing.
             Concurrent salvage therapy that is intended to be continued must be at a stable dose
             for ≥ 2 days prior to ALPN-101 dosing.

          8. Treatment for aGVHD with adoptive cell therapy, investigational agents, devices, or
             procedures ≤ 2 weeks or 5 half-lives—whichever is greater—prior to ALPN-101 dosing,
             unless approved by the medical monitor and sponsor; prior treatment with mesenchymal
             stem cells is permitted.

          9. Known allergies, hypersensitivity, or intolerance to study drug, excipients, or
             similar compounds.

         10. Any medical complications or conditions that would, in the investigator's judgment,
             interfere with full participation in the study, including administration of study drug
             and attending required study visits; pose a significant risk to the participant; or
             interfere with interpretation of study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Hillson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alpine Immune Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Hillson, MD</last_name>
    <phone>206-788-4545</phone>
    <email>jan.hillson@alpineimmunesciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kay Chanea</last_name>
      <phone>626-218-2340</phone>
      <email>kchanea@coh.org</email>
    </contact>
    <investigator>
      <last_name>Amandeep Salhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alireza Eghtedar, M.D.</last_name>
      <phone>720-754-4800</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Alireza Eghtedar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirenia Correa</last_name>
      <phone>305-243-9590</phone>
      <email>k.correa@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Trent Wang, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Morrison</last_name>
      <phone>913-558-7585</phone>
      <email>mmorrison3@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil Abhyankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Center for Blood Cancer</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Johnson</last_name>
      <phone>615-329-7662</phone>
      <email>heather.johnson@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Jeremy Pantin, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. David's South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Gordon</last_name>
      <phone>512-816-7399</phone>
      <email>rob.gordon@sarahcannon.com</email>
    </contact>
    <contact_backup>
      <last_name>Renee Stajanovic</last_name>
      <phone>512 816 6423</phone>
      <email>renne.stajanovic@sarahcannon.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aravind Ramakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>steroid-resistant acute graft versus host disease</keyword>
  <keyword>steroid-refractory acute graft versus host disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

